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Pseudomyxoma Peritonei (PMP) and Peritoneal Mesothelioma (PM) are both rare peritoneal malig-
nancies. Currently, affected patients may be treated with Cytoreductive Surgery and Hyperthermic
Intraperitoneal Chemotherapy offering long-term survival or even cure in selected patients. However,
many issues regarding the optimal treatment strategy are currently under debate.
To aid physicians involved in the treatment of these patients in clinical decision making, the PSOGI
executive committee proposed to create a consensus statement on PMP and PM. This manuscript de-
scribes the methodology of the consensus process.
The Delphi technique is a reliable method for attaining consensus on a topic that lacks scientiﬁc ev-
idence through multiple voting rounds which feeds back responses to the participants in between
rounds. The GRADE system provides a structured framework for presenting and grading the available
evidence. Separate questionnaires were created for PMP and PM and sent during two voting rounds to 80
and 38 experts, respectively. A consensus threshold of 51.0% was chosen.
After the second round, consensus was reached on 92.9%e100.0% of the questions. The results were
presented and discussed in the plenary session at the PSOGI 2018 international meeting in Paris. A third
round for the remaining issues is currently in progress.
In conclusion, using the Delphi technique and GRADE methodology, consensus was reached in many
issues regarding the treatment of PM and PMP amongst an international panel of experts. The main
results will be published in the near future.
© 2019 Published by Elsevier Ltd., Diffuse Malignant Peritoneal Mesothelioma; GRADE, Grades of Recommendation, Assessment, Development, and
l Chemotherapy; HIPEC, Hyperthermic Intraperitoneal Chemotherapy; LoE, Level of Evidence; MCPM, MultiCystic
Control, Outcome; PM, Peritoneal Mesothelioma; PMP, Pseudomyxoma Peritonei; PSOGI, Peritoneal Surface Oncology
ial; SC, Steering Committee; SoR, Strength of Recommendation(s); WDPPM, Well Differentiated Papillary Peritoneal
i.it (S. Kusamura).
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Pseudomyxoma peritonei (PMP) and Peritoneal Mesothelioma
(PM) are both rare peritoneal malignancies, affecting about one to
three in a million people each year [1,2]. Due to aspeciﬁc symptoms
and diagnostic limitations, it is usually discovered at an advanced
stage, limiting treatment options and decreasing prognosis.
Recently, Cytoreductive Surgery (CRS) followed by Hyperther-
mic Intraperitoneal Chemotherapy (HIPEC) has emerged as a
potentially curative treatment of PMP and PM. The advent of this
new treatment modality has signiﬁcantly improved the prognosis
of patients suffering from these diseases. However, many issues
regarding the management of these diseases remain under debate.
Due to the very low incidence of PMP and PM, randomized
controlled trials (RCT) addressing the various aspects of its man-
agement are currently lacking and highly unlikely to be performed
in the near future. Instead, it is desirable to harmonize current
clinical practice, bringing together expert opinions and experi-
ences, as well as the available literature to build a consensus based
guideline, especially in the most contentious issues. This may
facilitate clinical decision making by physicians being confronted
with this rare disease. The initiative for this guideline was proposed
by members of the PSOGI Executive Committee and will include an
update of the PMP consensus statement provided by the Peritoneal
Surface Oncology Group International (PSOGI) in 2008 [3].
Purpose of the current manuscript is to describe the method-
ology used for this consensus statement and to discuss the main
results.
Materials and methods
In this consensus statement for PMP and PM, we used two
techniques to describe the level of evidence (LoE), to create ques-
tionnaires, and to achieve consensus. Here, we will describe the
goals, approach, pros and cons, and reasons for choosing these
methodologies.
The Delphi technique
The term ‘Delphi’ originates from the Oracle of Delphi in Greek
mythology, which was frequently consulted in wars and before
making important decisions, for she was believed to predict the
future. The Delphi technique seeks to approximate the most valid
answer by assuming superiority of the judgment of a group over
the judgment of a single individual [4]. In contrast to a conventional
group meeting, the Delphi technique guarantees anonymity, does
not need to have all experts meet in person to give their opinion,
and provides feedback on the responses to create discussion. Also,
each participant can state their opinion independently of other
participants, which is usually not the case in a conventional
meeting where dominant participants will easily overrule less-
dominant participants [5]. The Delphi technique is increasingly
used over the past decades in various ﬁelds of medicine. Given
these advantages, the Delphi technique was chosen over conven-
tional questionnaires in the current project.
The Delphi technique is a reliable method for obtaining
consensus on a speciﬁc topic that lacks scientiﬁc evidence and
therefore relies on expert opinion. It consists of multiple voting
rounds in which a multiple-choice questionnaire is send to a group
of participants who are considered experts on the topic [6,7]. In
general, the more participants the better, as well as that it would be
preferable to pick experts from different backgrounds to create a
heterogeneous group with a broader knowledge level. This would
obviously contribute to the quality of the consensus [6]. After each
round, the results are summarized and returned to the participantsPlease cite this article as: Lurvink RJ et al., The Delphi and GRADEmethodo
Peritonei and Peritoneal Mesothelioma, European Journal of Surgical Onin a subsequent round. These results are returned to create a
debate, through which participants may reconsider their response
in the next round. There is no limitation to the number of rounds
with the Delphi technique [6,7]. Ideally, this will, for each question,
lead to reaching a pre-set threshold percentage of votes that is
considered consensus.
The GRADE system
The GRADE system (Grades of Recommendation, Assessment,
Development, and Evaluation) is used for setting up questions,
rating the quality of scientiﬁc evidence and stating either strong or
weak recommendations [5,8,9]. An advantage of the GRADE system
is the separate rating of the quality of evidence and the strength of
the recommendation (SoR), e.g. allowing in some cases a strong
recommendation despite low LoE [8]. The process is facilitatedwith
the structured framework that the GRADE system provides. The
superiority of the GRADE system as compared to other systems is
based on the fact that the GRADE system uses clear cut and
transparent rules for rating the evidence and stating recommen-
dations [9]. These explicitly deﬁned requirements are lacking in
other systems, reducing their scientiﬁc value.
According to the GRADE system, questions should be set up
according to the PICO-model: Patient, Intervention, Control,
Outcome [10]. This model is recommended by The Cochrane
Handbook for Systematic Reviews of Interventions to develop a
review question, thus ensuring that the relevant components of the
question are well deﬁned [11]. The PICO framework is primarily
centred on therapy questions, and although it can be adapted to
formulate research questions related to prognosis or diagnosis, it is
less suitable for other types of clinical information needs [12].
The LoE concerning each question was categorized into four
degrees: ‘high’, ‘moderate’, ‘low’, and ‘very low’ LoE. These levels
agree with a certain degree of conﬁdence in the estimate of the
effect [13]. In general, RCT's are classiﬁed as ‘high’ LoE, whereas
observational studies are considered ‘low’ or ‘very low’ LoE. How-
ever, a high risk of bias can decrease the LoE, while a low risk of bias
can increase the LoE [8,14]. After the quality of evidence has been
determined, balance between beneﬁts and harms, as well as the
patient's preferences, will be considered as well before providing a
recommendation [8]. Recommendations were either ‘strong’ or
‘weak’, and either ‘positive’ or ‘negative’, leading to four possible
options [15,16]. So, only after all these factors have been considered,
the expert panel was able to propose a certain recommendation
[17]. An overview and description of possible combinations and
their implications for recommendations are shown in Table 1.
Expert panel and questionnaire development
For the composition of the expert panel, the steering committee
(SC) started identifying surgeons and medical oncologists world-
wide with expertise in the management of PMP and/or PM, based
on centres’ peritoneal surface malignancies volume and scientiﬁc
production over the last two decades.
Concerning PM, more restrictive criteria were applied following
the French RENAPE network standards. The centre was deﬁned as
expert when they treat at least 15 (rare) peritoneal surface malig-
nancies per year and have experienced more than 100 CRS and
HIPEC procedures [18].
The SC also decided on which topics were to be included in the
questionnaires. The timeline of the meetings and voting rounds is
shown in Fig. 1.
Main topics to be included in the PMP questionnaires:
- Pathology terminology for histological classiﬁcationlogy used in the PSOGI 2018 consensus statement on Pseudomyxoma
cology, https://doi.org/10.1016/j.ejso.2019.03.012
Table 1
GRADE Strength of Recommendations and Quality of the Evidence (the combinations listed could be further subdivided in positive and negative categories according to the
direction of the balance between desirable and undesirable effects).
Strength of Recommendation
and Quality of Evidence
Clarity of balance between desirable
and undesirable effects
Methodological Quality of Supporting
Evidence (examples)
Implications
Strong recommendation, high-
quality evidence.
Desirable effects clearly outweigh
undesirable effects, or vice versa.
Consistent evidence from well-
performed RCTs or exceptionally strong
evidence from unbiased observational
studies.
Recommendation can apply to most
patients in most circumstances. Further
research is unlikely to change our
conﬁdence in the estimate of the effect.
Strong recommendation,
moderate quality evidence.
Desirable effects clearly outweigh
undesirable effects, or vice versa.
Evidence from RCTs with important
limitations (inconsistent results,
methodological ﬂaws, indirect, or
imprecise) or exceptionally strong
evidence from unbiased observational
studies.
Recommendation can apply to most
patients in most circumstances. Further
research (if performed) is likely to have an
important impact on our conﬁdence in the
estimate of effect and may change the
estimate.
Strong recommendation, low-
quality evidence.
Desirable effects clearly outweigh
undesirable effects, or vice versa.
Evidence for at least one critical
outcome from observational studies,
RCTs with serious ﬂaws or indirect
evidence.
Recommendation may change when higher
quality evidence becomes available. Further
research (if performed) is likely to have an
important impact on our conﬁdence in the
estimate of effect and is likely to change the
estimate.
Strong recommendation, very
low-quality evidence (very
rarely applicable).
Desirable effects clearly outweigh
undesirable effects, or vice versa.
Evidence for at least one critical
outcome from unsystematic clinical
observations or very indirect evidence.
Recommendation may change when higher
quality evidence becomes available; any
estimate of effect for at least one critical
outcome is very uncertain.
Weak recommendation, high-
quality evidence.
Desirable effects closely balanced with
undesirable effects.
Consistent evidence from well-
performed RCTs or exceptionally strong
evidence from unbiased observational
studies.
The best action may differ depending on
circumstances or patients or societal values.
Further research is unlikely to change our
conﬁdence in the estimate of the effect.
Weak recommendation,
moderate-quality of
evidence.
Desirable effects closely balanced with
undesirable effects.
Evidence from RCTs with important
limitations (inconsistent results,
methodological ﬂaws, indirect, or
imprecise) or exceptionally strong
evidence from unbiased observational
studies.
Alternative approaches likely to be better
for some patients under some
circumstances. Further research (if
performed) is likely to have an important
impact on our conﬁdence in the estimate of
effect and may change the estimate.
Weak recommendation, low-
quality of evidence.
Uncertainty in the estimates of
desirable effects, harms, and burden;
desirable effects, harms and burden
may be closely balanced.
Evidence for at least one critical
outcome from observational studies,
RCTs with serious ﬂaws or indirect
evidence.
Other alternatives may be equally
reasonable. Further research is very likely to
have an important impact on our
conﬁdence in the estimate of effect and is
likely to change the estimate.
Weak recommendation, very
low-quality evidence.
Major uncertainty in the estimates of
desirable effects, harms, and burden;
desirable effects may or may not be
balanced with undesirable effects.
Evidence for at least one critical
outcome from unsystematic clinical
observations or very indirect evidence.
Other alternatives may be equally
reasonable. Any estimate of effect, for at
least one critical outcome, is very uncertain.
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- Use of systemic chemotherapy
- Contra-indications for CRS and HIPEC
- Treatment of an (unexpected) appendiceal neoplasm at
appendectomy
- Treatment of premenopausal women
- Follow-up after CRS and HIPEC
Main topics to be included in the PM questionnaires:
- Diffuse Malignant Peritoneal Mesothelioma (DMPM):Pleas
Peritoo Elements required in the pathology report
o Pre-operative work-up
o Contra-indications for CRS and HIPEC
o Choice of HIPEC drug
o Treatment of premenopausal women
o Use of systemic chemotherapy
o Follow-up after CRS and HIPEC- Well Differentiated Papillary Peritoneal Mesothelioma
(WDPPM):o Indications for CRS with/without HIPEC
o Treatment of premenopausal women
o Use of systemic chemotherapy- MultiCystic Peritoneal Mesothelioma (MCPM)
o Indications for CRS with/without HIPEC
o Treatment of premenopausal womene cite this article as: Lurvink RJ et al., The Delphi and GRADEmethodology u
nei and Peritoneal Mesothelioma, European Journal of Surgical Oncology,o Use of systemic chemotherapyLiterature concerning these topics was searched in Pubmed and
Cochrane Library and summarized. We used the GRADE system to
build questionnaires for both PMP and PM.
Each question required two answers: one for rating the quality
of evidence (high, moderate, low, very low), and another for rating
the SoR (strong positive, weak positive, weak negative, strong
negative). To facilitate participants to give an evidence-based
answer, an overview of the literature as well as a summary
regarding the Delphi and GRADEmethodology have been provided.
Although the ﬁrst round of a Delphi generally consists of an
‘open response’ questionnaire, it was decided that all possible and
relevant clinical scenarios were included in multiple choice ques-
tions. The questionnaires were available with an online question-
naire tool (SurveyMonkey©), of which the weblinks were sent to
the participants by email (Appendix 1). Reminder e-mails were sent
to stimulate responses. After the ﬁrst round, the results were
summarized for each question and shown to the participants in the
second voting round.
The results of the second round were shown and discussed at
the PSOGI 2018 meeting in Paris. Here, a third round was proposed
to reach consensus on the few remaining questions, and to include
two rephrased questions from the PMP questionnaire due to lack of
clarity in the way they were previously formulated.sed in the PSOGI 2018 consensus statement on Pseudomyxoma
https://doi.org/10.1016/j.ejso.2019.03.012
Fig. 1. Flowchart and timeline of meetings and voting rounds.
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Expert panel
The PM expert panel consisted of 37 surgeons and 1 medicalPlease cite this article as: Lurvink RJ et al., The Delphi and GRADEmethodo
Peritonei and Peritoneal Mesothelioma, European Journal of Surgical Ononcologist, originating from 17 countries. The PMP expert panel
consisted of 69 surgeons and 11 medical oncologists, originating
from 28 countries (Table 2).logy used in the PSOGI 2018 consensus statement on Pseudomyxoma
cology, https://doi.org/10.1016/j.ejso.2019.03.012
Table 2
Number of experts and origin in each expert panel.
PM PMP
Specialty
Surgical Oncology 37 69
Medical Oncology 1 11
Country
Australia 1 5
Belgium 2 3
Brazil 0 2
Canada 1 2
China 2 2
Denmark 1 1
France 4 6
Germany 3 6
Greece 1 2
India 0 5
Israel 2 2
Italy 4 7
Japan 1 1
Netherlands 1 5
New Zealand 0 1
Norway 0 2
Poland 0 1
Saudi Arabia 0 1
Singapore 0 1
South Korea 0 1
Spain 1 4
Sweden 1 2
Switzerland 1 2
Taiwan 0 1
Turkey 0 1
UK 5 5
Ukraine 0 1
USA 7 8
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In total, 42 questions regarding PM and 69 questions regarding
PMP were formulated. PM questions were distributed over 3 ques-
tionnaires, regarding DMPM (27 questions), WDPPM (8 questions),
and MCPM (7 questions). The PMP questions were divided over 2
questionnaires; part I (34 questions) considered terminology and
pathological classiﬁcation, preoperative evaluation and diagnosis,
CRS and HIPEC, HIPEC regimen, management of diaphragmatic
disease and thoracic extension, Early Postoperative Intraperitoneal
Chemotherapy (EPIC), maximal tumour debulking, and follow-up.
Part II (35 questions) mainly focused on the use of systemic
chemotherapy and the management of the unexpected ﬁnding of
various types of appendiceal neoplasms at appendectomy.
The ﬁrst voting round of both PM and PMP took place in July
2018 over a period of 19 consecutive days. According to the Delphi
methodology, these results were shown in the questionnaires
during the second voting round, which was held in August 2018
and lasted 22 days.
Completion rates ranged from 67% to 82% during the ﬁrst round
and from 61 to 69% during the second round (Fig.1). Questionnaires
that had not been fully completed, were not taken into account in
the analyses.
Achieving consensus
Like in the 2006 PSOGI consensus process [3], we deﬁned that
consensus was reached when the cut-off point of 51.0% of the votes
at a question was obtained.
During the ﬁrst round, the participants graded the available LoE
on a 4-point scale from ‘very low’ to ‘high’. The interpreted LoE was
very variable, and an agreement was only achieved in a small
percentage of the questions (0.0%e17.6%). This level of agreementPlease cite this article as: Lurvink RJ et al., The Delphi and GRADEmethodo
Peritonei and Peritoneal Mesothelioma, European Journal of Surgical Oncchanged drastically during the second round, in which the partic-
ipants agreed on the LoE in 71.4%e96.9% of the questions.
A similar, but smaller, shift between the ﬁrst and second round
was seen in the questions regarding recommendations. During the
ﬁrst round, consensus regarding the recommendations was
reached for 60.0%e71.4% of the questions. This number had risen to
92.9%e100.0% during the second round. The amount of questions
on which consensus was reached per questionnaire and per round
are shown in Table 3.
Finally, we also analysed the voting behaviour of high-volume
PMP centres as compared to all PMP centres, since we hypoth-
esised that a high-volume centre could judge the LoE and SoR
differently than the other centres. These results are shown in
Table 4 and show no signiﬁcant differences in voting behaviour
between those two groups.
Discussion
This paper will be the ﬁrst of a series concerning the 2018 PSOGI
consensus statement for PM and PMP. With this consensus state-
ment, we seek to support other clinicians and (starting) HIPEC
centres worldwide in the treatment of these rare diseases. This
work provides a broad outline of the ﬁrst Delphi consensus state-
ment in peritoneal surface malignancies on such a large scale.
We used the Delphi technique and GRADE system to create a
structured and well-founded consensus statement. Although these
methods have numerous advantages, some limitations should be
taken into consideration and might affect validity, which we will
discuss below.
Advantages of using the Delphi technique and GRADE method
The Delphi technique provides anonymity, both when
answering the questionnaires as when receiving back the answers,
allowing all participants to express their opinion independently.
Giving feedback to responders intends to broaden knowledge and
stimulate new ideas, so participants might reconsider their answer
in the next voting round(s). This will ideally lead to achieving
consensus.
The GRADE system provides a structured framework for the
presentation and rating of scientiﬁc evidence that can be used in
systematic reviews and guidelines. An important advantage of the
GRADE system over other rating systems is that quality of evidence
and the SoR could eventually be rated separately, which means that
a strong recommendation can be given even though high quality
scientiﬁc evidence is lacking [8]. We considered this very helpful
for our consensus statement, since the quality of the evidence was
expected to be low; using the GRADE system, this low-quality ev-
idence does not rule out a strong recommendation.
Limitations
With the Delphi technique, the goal is to reach a pre-deﬁned
consensus threshold. However, it is unclear how to deﬁne this
threshold: scientiﬁc evidence on this matter is lacking, although it
is generally believed that increasing the threshold increases val-
idity [6,7].
We chose a 51.0% threshold, based on the previous PSOGI
consensus experience in 2006 [3]. Intuitively, a consensus state-
ment of 51.0% might be less valid than a statement of for example
71.0%, so we will take this into account when publishing the
consensus statements and recommendations. By reporting the
percentages of votes at each recommendation that achieved
consensus, we hope to be sufﬁciently transparent and to allow
readers to draw their own conclusions regarding eachlogy used in the PSOGI 2018 consensus statement on Pseudomyxoma
ology, https://doi.org/10.1016/j.ejso.2019.03.012
Table 3
Amount of questions per questionnaire on which consensus was reached during the ﬁrst two voting rounds.
Questionnaire Round 1, Consensus
on Level of Evidence
Round 2, Consensus
on Level of Evidence
Round 1, Consensus on
Recommendation
Round 2, Consensus on
Recommendation
PM
WDPPM 0/8 (0.0%) 7/8 (87.5%) 5/8 (62.5%) 8/8 (100%)
MCPM 1/7 (14.3%) 5/7 (71.4%) 5/7 (71.4%) 7/7 (100%)
DMPM 9/51 (17.6%) 47/51 (92.2%) 38/56 (67.9%) 53/56 (94.6%)
PMP
PMP-I 9/56 (16.1%) 50/56 (89.2%) 42/70 (60%) 65/70 (92.9%)
PMP-II 5/32 (15.6%) 31/32 (96.9%) 21/35 (60%) 34/35 (97.1%)
Table 4
Voting behaviour of expert centres as compared to all participating centres.
Level of Evidence Round 1 Round 2
High Moderate Low Very Low High Moderate Low Very Low
DMPM 23.3% 38.8% 31.7% 6.2% 19.8% 45.8% 32.3% 2.0%
Expert Centres MCPM 27.6% 30.5% 23.3% 18.6% 22.8% 49.7% 21.2% 6.3%
WDPPM 21.7% 31.7% 32.1% 14.6% 13.4% 41.7% 44.0% 0.9%
All Centres PMP-1 21.9% 39.3% 32.4% 6.3% 12.7% 54.0% 31.2% 3.1%
Expert Centres 19.4% 37.4% 35.0% 8.2% 12.7% 53.7% 31.3% 3.2%
All Centres PMP-2 11.7% 39.7% 43.1% 5.6% 2.0% 46.4% 50.6% 1.1%
Expert Centres 10.9% 37.9% 44.8% 6.4% 2.3% 47.3% 49.3% 1.0%
Strength of Recommendation Round 1 Round 2
High Moderate Low Very Low High Moderate Low Very Low
DMPM 32.5% 40.4% 8.1% 4.6% 33.1% 49.0% 4.9% 2.7%
Expert Centres MCPM 57.6% 29.0% 7.6% 5.7% 65.1% 19.0% 6.9% 9.0%
WDPPM 58.3% 30.4% 9.6% 1.7% 70.4% 21.8% 6.9% 0.9%
All Centres PMP-1 29.3% 33.5% 11.4% 5.5% 31.8% 43.2% 8.7% 4.7%
Expert Centres 28.6% 34.9% 11.3% 6.4% 32.0% 40.7% 9.0% 5.1%
All Centres PMP-2 24.4% 33.4% 25.4% 17.3% 23.6% 36.7% 21.6% 18.0%
Expert Centres 22.2% 32.5% 25.4% 20.4% 23.1% 36.5% 20.9% 19.4%
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The ﬁrst round of a Delphi consensus consists of an open-
response questionnaire, to reduce tunnel vision among the SC
and allow all possible answers in the next voting round [4]. We
deviated from this by starting immediately with the regular
multiple-choice questionnaire, although we tried to provide all
relevant answers, and added the option ‘other, please specify’ in
some questions. However, not starting with an open-response
questionnaire may have caused limited answers and could thus
reduce validity.
Evidence regarding the criteria for selection of experts and the
number of experts that are required for a valid Delphi consensus
statement is also lacking [6,7]. In general, the criteria for selection
are left to the SC, as well as the number of experts invited. The
available literature describes expert panels varying from only 4 to
3000 experts [4]. However, in contrast to popular believe that a
higher number of participants increases the reliability of the
consensus, there is very little evidence available that proves this [6].
Therefore, the decision about the size of the expert panel is prag-
matically chosen by the SC. Obviously, quality of the experts is
crucially important, so a large expert panel does not guarantee a
high-quality consensus statement [4]. Our expert panels consisted
of 38 (PM) and 80 (PMP) experts, and we consider this to be a
sufﬁcient number of experts, especially since our strict selection
criteria for the experts. Due to the low prevalence of these diseases,
only centres/experts with multiple years of experience with these
diseases were included in the expert panel, increasing the quality of
the consensus statements.
A downside of our expert panels is the limited number of
medical oncologists: the PM expert panel contained only 1 medical
oncologist, and the PMP expert panel contained 11 medicalPlease cite this article as: Lurvink RJ et al., The Delphi and GRADEmethodo
Peritonei and Peritoneal Mesothelioma, European Journal of Surgical Ononcologists. Since also questions regarding the use of systemic
treatment were included in the questionnaires, the opinion of more
medical oncologists could have affected the results concerning
these questions.
Finally, although both the Delphi technique and GRADE system
are useful methods for generating a consensus statement, it should
not be forgotten that both methods require a judgment or opinion
of the participants [6e8,10]. Although it is assumed that the judg-
ment of a group is more valid than the judgment of an individual,
neither judgment is necessarily absolutely correct.
Observations during voting
A decrease in the participation rate between the ﬁrst and second
rounds was observed. This is most probably due to the time
consuming process given the length of the questionnaires and the
summarized scientiﬁc literature that was added.
To stimulate responses, multiple e-mail reminders were sent to
the participants during each voting round. This is recommended by
other researchers that have used the Delphi technique as well, since
the Delphi technique is more time consuming than a standard
survey [7]. Other researchers that used the Delphi technique
describe varying degrees of participation, from 75% to 100% [7]. The
one study achieving a 100% response rate performed face-to-face
interviews in the ﬁrst round, which gives a personal touch and
increases the likelihood of participants to complete the question-
naires. In our case, this was unfortunately not possible, since our
experts originate from HIPEC-centres worldwide.
Consensus was reached during the ﬁrst voting round in 60.0%e
71.4% of the questions. This high level of disagreement shows us
how disharmonized clinical practice of PM and PMP currently is,logy used in the PSOGI 2018 consensus statement on Pseudomyxoma
cology, https://doi.org/10.1016/j.ejso.2019.03.012
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guideline.
Next, it was noted that the quality of the scientiﬁc literature
concerning the topics in the questionnaires was in general over-
estimated by the participants. The participants were asked to grade
the scientiﬁc literature for each topic on a 4-point scale: ‘high’,
‘moderate’, ‘low’, ‘very low’. According to the GRADE system, to rate
the evidence as ‘high’ quality, it should contain well-performed
RCT's or exceptionally strong evidence from unbiased observa-
tional studies. ‘Moderate’ quality of evidencewould consist of RCT's
with some limitations or strong evidence form unbiased observa-
tional studies. ‘Low’ quality of evidence is based on observational
studies or RCT's with indirect evidence; ‘very low’ quality is based
on unsystematic clinical observations or very indirect evidence.
Most of the available scientiﬁc evidence consisted of cohort/
observational studies, which had some scientiﬁc ﬂaws and gener-
ally contradicted each other. Therefore, the SC considered most of
the evidence as ‘low’ or even ‘very low’ quality of evidence. How-
ever, in many cases, the available evidence was rated by the par-
ticipants as ‘moderate’ or even ‘high’ quality of evidence. So, there is
a discrepancy between the perceived quality of evidence and the
actual quality of evidence, which might have inﬂuenced the SoR
given by the participants. We considered two possible explanations
for this phenomenon. In the ﬁrst place, we hypothesised that high
volume centres, who are undoubtedly perfectly competent to
phrase a recommendation regarding the clinical practice of treating
PM and PMP, tend to overrate the evidence and the SoR due to
difﬁculties in accurately perceiving the quality of evidence. This
would be evenmore difﬁcult for clinicians exclusivelyworkingwith
peritoneal surface malignancies, due to the general lack of high-
quality evidence in this ﬁeld. This hypothesis was proven to be
unlikely, as the voting behaviour of the high-volume centres is
comparable to lower volume centres, as shown in Table 4. Our
second hypothesis is related to the panellist perspective on how
much further research could advance in clarifying contentious is-
sues in PM and/or PMP. The best study design is well-known to be
the RCT that is unlikely to be successfully completed in PM and PMP
due to their extremely low prevalence. In Table 1, the last column
contains information regarding the implications of various possible
combinations between SoR and LoE. The higher the LoE, the lower
the chance that future research could change the estimate and
consequently the SoR. Therefore, the panellist might have
perceived that the SoR/LoE in the context of PM and/or PMP as
something more related to the feasibility of better-designed future
studies, rather than the type of study design. Consequently, the
panellist might have overrated the SoR/LoE in several questions,
considering the slim chance of studies of better quality being
conducted in the years to come that will be able to change the
current knowledge on PM and/or PMP.
Consensus was not yet reached on 15 questions after the two
voting rounds, mainly due to defaults in the design of the questions.
These questions were altered and will be included in the third
voting round, after whichwe aim to achieve consensus as well. Four
questions were added in the PMP e Unexpected Appendiceal
Finding section, since we realized that we had not included all
possible scenarios in the questionnaire.
Conclusion
To our knowledge, this consensus statement is currently the
only consensus statement regarding PM and PMP. With this
consensus statement, we seek to aid clinicians and HIPEC centres inPlease cite this article as: Lurvink RJ et al., The Delphi and GRADEmethodo
Peritonei and Peritoneal Mesothelioma, European Journal of Surgical Oncthe care and treatment for patients with PM or PMP. Although there
is some caveat in the execution of the Delphi and GRADE methods,
we reckon the results of this consensus statement very successful,
especially after seeing the disharmony in the recommendations
during the ﬁrst round, proving the requirement for this consensus
statement. Therefore, we aim to provide a valid guideline in which
consensus is reached in most of the questions. These results will be
published in multiple manuscripts over the course of 2019 and
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